报价延迟最少15分钟:2026/03/29 02:16 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
72.82 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
3.32/9.69
|
|
企业价值
2.26B
|
| 资产负债 |
|
每股账面净值
24.12
|
| 现金流量 |
|
现金流量率
0.12
|
| 损益表 |
|
收益
883.37M
|
|
每股收益
20.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology,rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically,it generates maximum revenue from the United States, followed by other markets. |
